GSK rejects claims that it has been profiteering from vaccine sales in UgandaBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6741 (Published 24 November 2010) Cite this as: BMJ 2010;341:c6741
- Paul Dinsdale
GlaxoSmithKline (GSK) has denied that it has been profiteering from the sale of its pneumonia vaccine to patients in the private sector in Uganda, after claims to the contrary by the medical charity Médicins Sans Frontières.
In a report in the Financial Times, the charity claimed that GSK had been making its Synflorix pneumoccocal vaccine available to more affluent patients in Uganda who were able to pay $50 (£31; €37) a dose for it.
Daniel Berman, deputy director of the MSF access campaign, said that GSK should provide the vaccine at the price of $7 a dose, which is the price agreed with the Global Alliance for Vaccines and Immunisation (GAVI), the UN supported body which is using funding from donor countries to buy pneumococcal vaccines at …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial